Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The hyperactivation of the sympathetic nervous system is a feature of the heart failure and
the determinants of disease progression and risk of sudden cardiac death. This research
project aims to study, in the drug use conditions provided in the summary of product
characteristics based on European marketing authorization (indications and dosage), the
effect of the Entresto® on the activity of sympathic nervous system using the reference
method, the microneurographic recording of sympathetic activity in muscle destiny (MSNA).
This study will try to determine if the double inhibition of AT1 receptor and neprilysin
activity result in lower sympathic nervous system burst rate versus single AT1 receptor
inhibition using angiotensin-converting-enzyme inhibitor or AT1 receptor of angiotensin II
inhibitor.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Toulouse
Treatments:
Angiotensin II Angiotensin-Converting Enzyme Inhibitors Angiotensinogen Enzyme Inhibitors LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan